<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490058</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000950</org_study_id>
    <nct_id>NCT03490058</nct_id>
  </id_info>
  <brief_title>The Prevention Options for Women Evaluation Research (POWER) Cohort</brief_title>
  <official_title>A Cohort for Evaluation of Open-label PrEP Delivery Among Kenyan and South African Women: The POWER Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Desmond Tutu HIV Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wits Reproductive Health and HIV Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The POWER Cohort study is a PrEP implementation project to demonstrate Pre-exposure
      prophylaxis (PrEP) delivery for young women in Cape Town and Johannesburg, South Africa and
      Kisumu, Kenya.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PrEP will be delivered to young women according to emerging national guidelines in family
      planning clinics (Kisumu, Kenya), youth friendly clinics (Johannesburg, South Africa), and
      mobile youth friendly clinics (Cape Town, South Africa). The investigators will evaluate PrEP
      delivery and follow cohorts of young women at each clinic location to understand PrEP uptake
      and use. In the Kisumu clinics, the investigators will also offer expedited partner therapy
      and partner HIV self-tests to women who test positive for chlamydia and/or gonorrhea. At one
      clinic in Johannesburg, the investigators will evaluate the use of a decision support tool to
      improve the decision to initiate PrEP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate PrEP delivery models for young women in different settings and geographies.</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Mixed methods assessment of how PrEP is implemented at the user, provider, health care facility, and community levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PrEP initiation</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Measure the number of young women who initiate PrEP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PrEP adherence</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Adherence by young women to PrEP. Adherence will be measured by the timing of PrEP refills and self-reported PrEP use. Blood samples for detection and quantification of PrEP levels (testing in batch) will be done for those who seroconvert to HIV and a subset who remain HIV uninfected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV seroconversion</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Assess HIV incidence during PrEP use and non-use.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess cost and cost-effectiveness of PrEP when delivered in public health clinics.</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Time-motion studies will be conducted to define the cost and cost effectiveness of the intervention in terms of HIV infections averted, disability-adjusted life years saved, and incremental cost-effectiveness of PrEP over routine HIV care.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the acceptability of delivering expedited partner therapy.</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Measure the number of women who accept STI expedited partner therapy and HIV self-test kits for their partners.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess the effect of a decision support tool on PrEP uptake</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Using a randomized design, evaluate if a decision support tool increases PrEP uptake.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Young women</arm_group_label>
    <description>Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.</description>
    <arm_group_label>Young women</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Dried blood spots
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sexually active HIV uninfected women ages 16-25 will be recruited from family planning
        clinics, youth clinics, and youth outreach programs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 16-25 (16 and 17 year olds, where permissible by national regulations and local
             IRB approval)

          -  Able and willing to provide written informed consent

          -  Recently sexually active (defined as having had vaginal intercourse at least once in
             the previous three months)

          -  HIV uninfected based on negative HIV rapid tests, on the date of enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie L Celum, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jared M Baeten, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel Johnson, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Morton, MPH</last_name>
    <phone>206-520-3832</phone>
    <email>jfmorton@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Johnson, MPH</last_name>
    <phone>206-520-3864</phone>
    <email>rjohnso@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kenya Medical Research Institute</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Bukusi, MBChB, MMed, MPH, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda-Gail Bekker, MBChB, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sinead Delany-Moretlwe, MBChB, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Connie Celum</investigator_full_name>
    <investigator_title>Prof of Medicine &amp; Global Health, Adjunct Prof of Epidemiology, SOM: Global Health</investigator_title>
  </responsible_party>
  <keyword>pre-exposure prophylaxis</keyword>
  <keyword>young women</keyword>
  <keyword>delivery of health care</keyword>
  <keyword>HIV infections/prevention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from the POWER Cohort Study will be available at the end of the project by contacting the Principal Investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

